Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200

Journal of Clinical Oncology

Volumn 25, Issue 12, 2007, Pages 1539-1544

  Giantonio, Bruce J ^a   Catalano, Paul J ^a   Meropol, Neal J ^a   O'Dwyer, Peter J ^a   Mitchell, Edith P ^a   Alberts, Steven R ^a   Schwartz, Michael A ^a   Benson III, Al B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ONCOLOGY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SALVAGE THERAPY; SINGLE BLIND PROCEDURE; SURVIVAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROBABILITY; RISK ASSESSMENT; SALVAGE THERAPY; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 34248173883     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.6305     Document Type: Article

References (27)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer Statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence: SEER 9 Regs Public-Use (1973-2002). Bethesda, MD, National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission
3. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
4. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
5. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95-98, 1996
6. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
7. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543, 1999
8. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
9. Margolin K, Gordon MS, Holmgren E, et al: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 19:851-856, 2001
10. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
11. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
12. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
15. Lan KKG, DeMets DL: Discrete seguential boundaries for clinical trials. Biometrika 70:659-663, 1983
16. Jennison, Turnbull BW: Interim analyses: The repeated confidence interval approach. J R Stat Soc, Series B 51:305-361, 1989
17. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 40:819-825, 1984
18. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
20. Cox DR: Regression models and life tables. J R Stat Soc, Series B 34:187-220, 1972
21. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
22. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
23. Manley PW, Martiny-Baron G, Schlaeppi JM, et al: Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 11:1715-1736, 2002
24. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
25. Kabbinavar F, Johnson DH, Langmuir VK, et al: Patterns of tumor progression during therapy with bevacizumab (BV) and chemotherapy (CT) for metastatic colorectal cancer (MCRC) and advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:277a, 2001 (abstr 1105)
26. Johnson DH, Devore R, Kabbinavar F, et al: Carboplatin (C) + paclitaxel (T) + rhumab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc Am Soc Clin Oncol 21:315a, 2001 (abstr 1256)
27. Devore R, Fehrenbacher L, Herbst H, et al: A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 19: 485a, 2000 (abstr 1896)